Bonevista solution for infection. 1mg/ml the syringe in a computer. with a needle of 3 ml No. 1 ***

Solution for Bonevist's injections is shown for treatment of osteoporosis at women during the post-menopausal period with the increased risk of changes. Reduction of risk of vertebralny changes is shown, the efficiency on prevention of fractures of neck of a hip is not established.

Structure

Active ingredient: ibandronic acid;

ibandronovy acid - 3 mg in the form of sodium of the ibandronat of monohydrate - 3.375 mg;

Concentration of ibandronovy acid in solution for injections - 1 mg/ml;

Excipients: ice acetic acid, sodium acetate trihydrate, sodium chloride, water for injections.

Contraindication

Hypersensitivity to ibandronovy acid or to any other component of drug.

Route of administration

Recommended dose of ibandronovy acid makes 3 mg in the form of an intravenous injection lasting 15-30 seconds, each 3 months. Drug is intended only for intravenous administration.

to Patients needs to accept calcium and vitamin D in addition.

If a planned dose it is passed, the injection of medicament should be made at once as soon as it is possible. Further the injection needs to do each 3 months from the moment of the last administration of drug.

. It is necessary to reconsider periodically a question of need of continuation of treatment taking into account advantage and potential risk of use of the medicament Bonevista for each patient separately, especially after 5 or more years of use of drug.

Feature of use

Pregnant

it is not applied.

Children

it is not applied.

Drivers

does not influence.

Overdose

Specific information on overdose treatment.

Considering the available knowledge of bisfosfonata, the overdose at intravenous administration can lead to a hypocalcemia, a hypophosphatemia and a hypomagnesiemia. Clinically significant decrease in serumal levels of calcium, phosphorus and magnesium should be adjusted administration of calcium of a gluconate, potassium phosphate or sodium and magnesium sulfate respectively.

Side effects

• from the immune system: seldom - exacerbation of bronchial asthma is rare - reactions of hypersensitivity, is very rare - anaphylactic reactions / shock.
• from nervous system: often - a headache, sometimes - dizziness.
• from an organ of sight: seldom - inflammation of an eye.
• from digestive tract: often - an esophagitis, gastritis, a gastroesophageal reflux disease, dyspepsia, diarrhea, an abdominal pain, nausea sometimes - an esophagitis, including ulcerations of a gullet or a stricture and a dysphasia, vomiting, a meteorism; seldom - a duodenitis.
• from skin and hypodermic cellulose: often - rash.

Interaction

Bioavailability at oral administration of ibandronovy acid decreases in the presence of food. In particular, food, calciferous, including milk and other polyvalent cations (aluminum, magnesium, iron) can break medicament Bonevista absorption that matches the results received in researches on animals. Therefore the medicament Bonevista should be taken after night starvation (not less than 6 hours).

to Store

at a temperature not above 30ºС.

to Store

out of children's reach.

Expiration date - 2 years.